| Bioactivity | MYX1715 is an inhibitor for N-Myristoyltransferase (NMT) with KD of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin[1][2]. |
| CAS | 2445448-66-6 |
| Formula | C25H29ClN6O2 |
| Molar Mass | 480.99 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang J, et al. Dysregulation of MYC-Family Proteins Sensitises Cancers to NMT Inhibition: Identification of NMTi Sensitivity and Mechanism[J]. Cancer Research, 2023, 83(7_Supplement): 4871-4871. [2]. Carr R, et al. N-Myristoyltransferase (NMT) inhibitors are completely novel payloads for Antibody Drug Conjugates that deliver extensive tumor regression at well tolerated doses[J]. |
MYX1715
CAS: 2445448-66-6 F: C25H29ClN6O2 W: 480.99
MYX1715 is an inhibitor for N-Myristoyltransferase (NMT) with KD of 0.09 nM. MYX1715 inhibits the proliferation of LU088
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.